Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801

 Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801

Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801

Shots:

  • Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801, which will be shared with Sanofi (partner in the discovery and the development of EVT801)
  • Kazia to get an exclusive WW license for research, development, and commercialization of EVT801. Kazia plans to evaluate EVT801 both as monothx. and in combination with immunotherapy for oncology indications
  • Evotec will provide CMC and manage the P-I trial of the therapy while Kazia will responsible for subsequent clinical evaluation & commercialization of EVT801

Click here to­ read full press release/ article | Ref: Evotec | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post